The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.
Evidence and Process for Translation of Pharmacogenetic Information (e.g., CYP 2C9 polymorphisms) into Label Updates for Approved Products, Advisory Committee for Pharmaceutical Science- Clinical Pharmacology Subcommittee meeting November 14, 2005
Advisory Committee Information Labeling Recommendations for Drugs/Biologics and Device Related to Pharmacogenomic Data and Test [PDF]
How New Insights into Pharmacogenomics Lead to Revisions of Product Labels [PPT]
FDA Pharmacogenetic Labels: A clinical perspective [PPT]
2004
Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, discussed at the FDA Advisory Committee for pharmaceutical sciences and Clinical Pharmacology Subcommittee meeting. Issues drug interaction concept paper. Rockville, MD. November 3, 2004.
Huang, S, Issues and Challenges in the Evaluation and Labeling of Drug Interaction Potentials of NME, Advisory Committee for Pharmaceutical Science- Clinical Pharmacology Subcommittee meeting, April 23, 2003, Rockville, MD.